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Hippo signaling acts as a tumor suppressor pathway 
by inhibiting the proliferation of adult stem cells and 
progenitor cells in various organs. Liver-specific deletion of 
Hippo pathway components in mice induces liver cancer 
development through activation of the transcriptional 
coactivators, YAP and TAZ, which exhibit nuclear enrichment 
and are activated in numerous types of cancer. The 
upstream-most regulators of Warts, the Drosophila ortholog 
of mammalian LATS1/2, are Kibra, Expanded, and Merlin. 
However, the roles of the corresponding mammalian 
orthologs, WWC1, FRMD6 and NF2, in the regulation of 
LATS1/2 activity and liver tumorigenesis in vivo are not fully 
understood. Here, we show that deletion of both Wwc1 and 
Nf2 in the liver accelerates intrahepatic cholangiocarcinoma 
(iCCA) development through activation of YAP/TAZ. 
Additionally, biliary epithelial cell-specific deletion of both 
Lats1 and Lats2 using a Sox9-CreERT2 system resulted in 
iCCA development through hyperactivation of YAP/TAZ. 
These findings suggest that WWC1 and NF2 cooperate to 
promote suppression of cholangiocarcinoma development by 
inhibiting the oncogenic activity of YAP/TAZ via LATS1/2.
Keywords: cholangiocarcinoma, Hippo pathway, NF2, 
WWC1, YAP
INTRODUCTION
Hippo signaling has been highlighted as a strong tumor-sup-
pressor pathway (Choi et al., 2018; Yu et al., 2015). Compo-
nents of the Hippo pathway, discovered initially in Drosophila 
through genetic screenings, are known to be well conserved 
in mammals. These mammalian orthologs (with Drosophila 
components in parentheses) are as follows: large tumor-sup-
pressor kinase 1 and 2 [LATS1/2] (Wts), mammalian ste20-
like kinase 1 and 2 [MST1/2] (Hpo), Salvador homolog 1 
[SAV1] (Sav), neurofibromatosis type 2 [NF2] (Mer), MOB 
kinase activator 1A and B [MOB1A/B] (Mats), WW and C2 
domain-containing 1, 2, and 3 [WWC1/2/3] (Kibra), and 
FERM-domain containing 6 [FRMD6] (Ex) (Baumgartner 
et al., 2010; Genevet et al., 2010; Halder and Johnson, 
2011; Pan, 2007). LATS1/2 kinases phosphorylate the tran-
scriptional coactivators, Yes-associated protein 1 (YAP) and 
WW-domain–containing transcription regulator 1 (TAZ) (Yki 
in Drosophila), thereby sequestering them in the cytoplasm 
and rendering them transcriptionally inactive. YAP and TAZ 
(YAP/TAZ) regulate genes related to lineage specification, 
self-renewal and the survival of various types of cells, includ-
ing stem/progenitor cells (Camargo et al., 2007; Choi et al., 
2018; Cordenonsi et al., 2011; Gregorieff et al., 2015; Ha-
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yashi et al., 2015; Heallen et al., 2013; Moon et al., 2018).
 To clarify the physiological roles and regulatory mechanism 
of the mammalian Hippo pathway, researchers have generat-
ed various tissue-specific knockout mice. In the liver, YAP not 
only serves as a critical factor during the development of bile 
ducts but also performs a decisive role during regeneration 
after liver damage (Lu et al., 2018; Zhang et al., 2010). Over-
expression of active YAP results in enlargement of the liver 
with dysplastic changes in hepatocytes. Liver-specific knock-
out of the upstream components of the Hippo pathway, 
Mst1/2, Sav1 or Nf2, induces the development of cancers 
with different histological features. Mice with liver-specific 
knockout of Mst1/2 predominantly develop hepatocellular 
carcinoma (HCC) rather than intrahepatic cholangiocarcino-
ma (iCCA)(Song et al., 2010; Zhou et al., 2009). Ablation 
of Mob1a/b in the mouse liver induces the development of 
mixed HCC/iCCA, as does Nf2 or Sav1 knockout. In addition, 
loss of either of these genes also causes different degrees of 
progenitor cell expansion (Benhamouche et al., 2010; Lee et 
al., 2010; Nishio et al., 2016; Song et al., 2010). Although 
NF2 has been shown to regulate LATS1/2 in vitro through 
binding to WWC1, Wwc1 single-knockout mice do not show 
any abnormal liver phenotypes (Makuch et al., 2011). How-
ever, Wwc1/Wwc2 double knockout causes development of 
mixed HCC/iCCA within 1 year (Hermann et al., 2018), sug-
gesting that other regulators are involved in the suppression 
of tumorigenesis to compensate the loss of WWC1. These 
previous results suggest that full activation of LATS cannot be 
achieved through WWC1 alone. Therefore, we hypothesized 
that WWC1 promotes activation of LATS through cooper-
ation with NF2 in mammals, much as the complex of Kibra 
and Mer regulates and activates Hpo in Drosophila (Su et 
al., 2017). Here, we generated liver-specific Nf2 and Wwc1 
double-knockout mice; notably, these mice died of iCCA at 
3 to 4 weeks of age. To more specifically study the cellular 
origin of YAP activation-driven iCCA, we also generated mice 
in which both Lats1 and Lats2 were deleted only in biliary epi-
thelial cells using a Sox9-CreERT2 system. Using these mice, we 
found that loss of Lats1/2 rapidly leads to iCCA development 
through YAP/TAZ activation. Therefore, our findings suggest 
that WWC1 and NF2 act cooperatively to regulate LATS1/2-
YAP in biliary epithelial cells of the liver and function as strong 
tumor suppressors on the path to iCCA development.
MATERIALS AND METHODS
Mice
Wwc1-/-, Nf2fl/fl, Lats1fl/fl, Lats2fl/fl, albumin-Cre transgenic 
(Tg) mice (B6.Cg-Tg(Alb-Cre)21Mgn/J), and Sox9-CreERT2 Tg 
((Sox9-Cre/ERT2)1Msan/J) (JAX 018829) have been previ-
ously described (Giovannini et al., 2000; Heallen et al., 2011; 
2013; Kim et al., 2013; Kopp et al., 2011; Makuch et al., 
2011). Wwc1-/- (B6.129S6(Cg)-Wwc1tm1.1Rlh/J, 0244) and 
Sox9-CreERT2 mice were obtained from The Jackson Labora-
tory (USA). All mice were housed in a specific pathogen-free 
facility with a temperature- and light-controlled environment. 
Experiments with mice were performed according to guide-
lines of the Institutional Animal Care and Use Committee 
(IACUC) of the Korea Advanced Institute of Science and 
Technology (KAIST) (No. KA2010-23). Wwc1-/-, Nf2fl/fl, and 
albumin-Cre mice were sacrificed when moribund for histo-
logical and molecular analyses. Four to eight week-old male 
Lats1fl/fl, Lats2fl/fl, and Sox9-CreERT2 mice were induced with a 
single dose of tamoxifen (125 mg/kg) and later sacrificed for 
analyses.
Histological, immunohistochemical and immunofluores-
cence staining
Mice were perfused with phosphate-buffered saline (PBS) 
and their liver tissues were harvested and fixed by incubating 
with 10% formalin overnight at 4°C. After paraffin embed-
ding, liver tissue blocks were cut into 4-μm-thick sections for 
H&E, immunohistochemical (IHC), and immunofluorescence 
(IF) staining. Deparaffinized and rehydrated sections were 
subjected to antigen retrieval in citrate buffer (10 mM tri-so-
dium citrate, 0.05% Tween 20, pH 6.0), after which endog-
enous peroxidase was blocked by incubating with 1% H2O2 
for 10 min. Sections were then incubated in blocking buffer 
(3% bovine serum albumin and 0.3% Triton X-100 in PBS) 
at room temperature, followed by incubation overnight at 
4°C with primary antibodies (Supplementary Table S1). After 
washing for 30 min to remove primary antibody, sections 
were incubated with horseradish peroxidase (HRP)-conjugate 
secondary antibodies at room temperature for 1 h, and then 
washed thoroughly again to remove secondary antibodies. 
Sections were then developed using a DAB Substrate Kit 
(Vector Laboratories, USA), and nuclei were counterstained 
with hematoxylin. N-cadherin and S100P were stained using 
a VENTANA BenchMark System (Roche Diagnostics, Switzer-
land).
 For IF staining, the same procedure as above was per-
formed, excluding the H2O2 blocking step, and fluorescent 
secondary antibodies were used instead of HRP-conjugated 
secondary antibodies (Supplementary Table S1). All antibod-
ies were diluted in blocking buffer.
Reverse transcription PCR and quantitative PCR
Total RNA was isolated from homogenized liver tissues using 
easy-Blue Total RNA Extraction Kit (iNtRON Biotechnology, 
Korea). cDNA was then synthesized from 2 μg of total RNA 
with M-MLV reverse transcriptase (Enzynomics, Korea) using 
a mixture of oligo dT and random hexamers, according to the 
manufacturer’s instructions. Quantitative polymerase chain 
reaction (qPCR) was performed on a CFX Connect Thermocy-
cler (Bio-Rad, USA) using SYBR Green 2X Premix (Enzynom-
ics) and the primers are listed in Supplementary Table S2.
Immunoblotting
Total protein was isolated from liver tissues using a lysis buf-
fer (50 mM Tris-Cl pH 7.5, 150 mM NaCl, 0.1% SDS, 0.5% 
sodium deoxycholate, and 1 mM EDTA) containing prote-
ase and phosphatase inhibitors (1 mM NaF, 1 mM Na3OV4, 
phenylmethylsulfonyl fluoride [PMSF], leupeptin, and pep-
statin; all from Sigma, USA) for 30 min on ice. After mea-
suring the concentration of protein in lysates using a Pierce 
BCA protein assay kit (Thermo Fisher Scientific, USA), lysates 
containing equal amounts of protein (15 μg) were resolved 
by sodium dodecyl sulfate-polyacrylamide gel electrophore-
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sis (SDS-PAGE). After transferring proteins to nitrocellulose 
membranes, blots were incubated overnight at 4°C with pri-
mary antibodies. After washing for 30 min with Tris-buffered 
saline (TBS) containing 0.1% Tween-20 (0.1% TBS-T), blots 
were incubated with secondary antibodies, diluted in TBS-T 
containing 5% skim milk. Blots were washed for 30 min with 
0.1% TBS-T and then developed using ECL Westsave Gold 
(Abfrontier, Korea).
Human tissue array staining
Human normal tissue arrays (BN501a) and tissue arrays of 
different stages of liver iCCA (LV1004) were purchased from 
US Biomax (USA). Slides were incubated at 60°C for 1 h, 
after which immunohistochemistry was performed on a VEN-
TANA BenchMark System using anti-YAP (1:100; Santa Cruz 
Biotechnology, USA) and anti-NF2 (1:200; Sigma) antibodies.
Statistical analysis
Graphing and statistical analyses (paired two-tailed Student’s 
t-test and two-tailed Fisher’s exact test) were performed us-
ing GraphPad Prism 6 software (GraphPad Software, USA).
RESULTS
Concurrent deletion of Wwc1 and Nf2 in the liver acceler-
ates iCCA development in mice
To investigate potential cooperativity between NF2 and 
WWC1 in mammals, we crossed albumin-Cre mice with 
Nf2fl/fl and Nf2fl/fl;Wwc1-/- mice to generate liver-specific Nf2 
single-knockout and Nf2; Wwc1 double-knockout mice. 
Remarkably, these Nf2fl/fl;Wwc1-/-;albumin-Cre (hereafter, 
Nf2;Wwc1 DKO) mice showed severe cachexia and abdomi-
nal distension within 2 weeks after birth; their livers were also 
enlarged and presented large tumor nodules; in contrast, no 
changes were observed in livers of Wwc1-/- (hereafter, Wwc1 
KO) mice (Fig. 1A). As previously reported, Nf2-deficient 
livers (Nf2fl/fl;albumin-Cre, hereafter Nf2 KO) showed a slight 
increase in size at a time when Nf2;Wwc1 DKO livers exhib-
ited obvious tumor nodules (Fig. 1B). Autophosphorylation 
of LATS was also dramatically decreased in Nf2;Wwc1 DKO 
mice (Fig. 1C). A histopathological analysis of H&E-stained 
slides of Nf2;Wwc1 DKO livers confirmed the development of 
iCCA, but not HCC (Figs. 1D and 1E). To further confirm iCCA 
development in the Nf2;Wwc1 DKO liver, we performed co-
IF staining for the cholangiocyte and hepatocyte markers, 
cytokeratin 19 (CK19) and hepatocyte nuclear factor 4a (HN-
F4a), respectively (Fig. 1F). The Nf2;Wwc1 DKO liver exhib-
ited high-grade cancer with malignant atypic cells, whereas 
the Nf2 KO liver showed minor expansion of cholangiocytes, 
which did not undergo dysplastic changes at the time point 
analyzed. Extensive desmoplastic reactions composed of 
a large number of fibroblasts surrounding the tumor were 
also observed in Nf2;Wwc1 DKO livers (Fig. 1G). Ultimately, 
Nf2;Wwc1 DKO mice died of iCCA within 3-4 weeks.
Increased YAP/TAZ activity promotes early development of 
iCCA in the Nf2;Wwc1 DKO liver
In line with the Western blotting results (Fig. 1C), IHC stain-
ing for YAP and TAZ in livers of 2-week-old control, Nf2 KO, 
Wwc1 KO, and Nf2;Wwc1 DKO mice revealed activation of 
YAP/TAZ in mutant livers. Indeed, some hepatocytes in Nf2 
KO livers also showed nuclear YAP, and most hepatocytes 
and atypical tumor cells from Nf2;Wwc1 DKO livers were 
strongly positive for YAP and TAZ (Figs. 2A and 2B). Fur-
thermore, these atypical tumor cells in periportal regions in 
Nf2;Wwc1 DKO livers were highly proliferative compared 
with those in the Nf2 KO liver, which showed moderate pro-
liferation (Fig. 2C).
 Only Nf2;Wwc1 DKO livers showed significant downreg-
ulation of hepatocyte-related genes together with upregula-
tion of cholangiocyte-related genes (Fig. 2D). As expected, 
the upregulation of YAP target genes was more pronounced 
in Nf2;Wwc1 DKO livers than in other mutant livers (Fig. 2D). 
The fibrosis-related genes, Vim and Col1a1, were also mod-
erately increased in the Nf2;Wwc1 DKO liver. Taken together, 
these results reveal the redundant and compensatory rela-
tionship between NF2 and WWC1 that regulates YAP/TAZ 
activity to prevent iCCA development.
Biliary epithelial cell-specific deletion of Lats1/2 in mice 
promotes iCCA development
Many liver-specific knockout mouse models of Hippo compo-
nents commonly show over-proliferation of biliary/progenitor 
cells, which further develops into HCCs or mixed HCC/iCCA 
(characteristics of both HCC and iCCA) (Benhamouche et al., 
2010; Lee et al., 2010; Nishio et al., 2016; Zhang et al., 2010). 
Since knockout of Hippo components in these studies was 
achieved using an albumin-Cre system, which is expressed in 
hepatoblasts during embryonic liver development and contin-
ues to hepatocytes in the adult liver, both hepatic progenitor 
cells and dedifferentiated transformed hepatocytes might 
contribute to the development of mixed HCC/iCCA. Intrigu-
ingly, Nf2;Wwc1 DKO mice developed iCCA, but not HCC or 
mixed HCC/iCCA, unlike previously documented knockout 
mice lacking liver-specific expression of Hippo components. 
Therefore, to ascertain whether activation of YAP specifically 
in intrahepatic cholangiocytes drives iCCA development, we 
generated a biliary epithelial cell (BEC)-specific Lats1/2 dou-
ble-knockout mouse model by crossing Sox9-CreERT2 mice 
with a Lats1fl/fl;Lats2fl/fl mouse model (Lats1fl/fl;Lats2fl/fl;Sox9 
CreERT2; hereafter, BEC-specific Lats1/2 DKO). We further 
crossed these mice with R26-Tdtomato reporter mice to trace 
the lineage of Lats1/2 deleted cells.
 Upon BEC-specific deletion of Lats1/2 at 4 weeks of age, 
BEC-specific Lats1/2 DKO mice showed severe jaundice, 
which changed the color of the liver to yellow. Although tiny 
nodules were detectable on the surface of the BEC-specific 
Lats1/2 DKO liver, the liver itself showed no marked increase 
in size. A histopathological examination of H&E-stained sec-
tions revealed atypical, dysplastic biliary epithelial cancer cells 
within the BEC-specific Lats1/2 DKO liver (Fig. 3A). IHC stain-
ing for YAP and TAZ showed increased staining intensities 
within iCCA lesions, and immunostaining for Ki67 confirmed 
their proliferative feature (Fig. 3A). Co-IF staining for CK19 
and tdTomato in BEC-specific Lats1/2 DKO mice revealed that 
CK19+ cells originated from Lats1/2-depleted BECs, and not 
from hepatocytes (Fig. 3B). Moreover, co-IF staining for CK19 
and HNF4a further supported the interpretation that iCCAs 
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that developed in the BEC-specific Lats1/2 DKO liver are tru-
ly derived from BECs (Fig. 3B). Sirius Red staining was also 
increased, reflecting the expansion of fibroblastic cells in the 
BEC-specific Lats1/2 DKO liver (Fig. 3C). As expected, expres-
sion levels of YAP target genes were significantly increased in 
the BEC-specific Lats1/2 DKO liver (Fig. 3D). On the basis of 
Fig. 1. Loss of NF2 and WWC1 in the liver induces iCCA. (A) Images of livers from 2-week-old control, Nf2 KO, and Nf2;Wwc1 DKO 
mice. (B) Ratio of liver weight (LW) to body weight (BW) for each genotype. (C) Western blot analysis of liver lysates from each mouse 
genotype. (D) Representative images of H&E-stained livers from each genotype of mice at postnatal day 1 (upper row; scale bars = 25 
μm) and postnatal week 3 (lower row; scale bars = 100 μm). (E) Magnifications of images in panel D (scale bars = 25 μm). (F) Images of 
co-IF staining with antibodies against CK19 and HNF4a (white arrowheads indicate cholangiocytes; scale bars = 50 μm). (G) Images of 
Sirius red/Fast green staining in livers of 2-week-old mice (black arrowheads indicate accumulated collagen stained with Sirius Red; scale 
bars = 100 μm).
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these results, we conclude that Lats1/2 deletion in intrahe-
patic BECs leads to iCCA development through activation of 
YAP/TAZ in the liver.
iCCAs that develop in knockout mice lacking Hippo path-
way components resemble human iCCAs
Human iCCA has been categorized into types 1 and 2 based 
on mucin productivity and immunophenotypes (Hayashi et 
al., 2016). In the present work, Alcian-blue staining of iC-
CAs in both Nf2;Wwc1 DKO and BEC-specific Lats1/2 DKO 
livers revealed very small amounts of mucin components, 
indicating that the tumors of both genotypes are composed 
of low-mucin–producing cancer cells (Fig. 4A). S100 calci-
um-binding protein P (S100P) immunostaining was faint 
in these cancer cells, but was high in non-epithelial cells of 
iCCAs that developed in Nf2;Wwc1 DKO and BEC-specific 
Lats1/2 DKO mice (Fig. 4B). We further found that BEC-spe-
cific Lats1/2 DKO and Nf2;Wwc1 DKO cancer cells adopted 
mesenchymal characteristics, as evidenced by positive stain-
ing for N-cadherin (Fig. 4C). Collectively, these data strongly 
support the conclusion that iCCAs that develop in Nf2;Wwc1 
DKO and BEC-specific Lats1/2 DKO livers are similar to type 2 
iCCA in human patients.
Fig. 2. YAP/TAZ are highly activated in both NF2- and WWC1-deficient cells. (A-C) Images of IHC staining with antibodies against YAP 
(A), TAZ (B), and Ki67 (C) in livers of 2-week-old mice (black and red arrowheads indicate cholangiocytes and hepatocytes, respectively; 
scale bars = 25 μm). (D) mRNA expression levels of hepatocyte related genes (Hnf4a and Cyp7a1), cholangiocyte-related genes (Krt7 and 
Krt19), YAP target genes (Cyr61, Ctgf, Ankrd1), and fibrosis related genes (Vim and Col1a1) in livers of 2- to 3-week-old mice.
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Expression of NF2 and YAP in human iCCA specimens
Previous studies have shown that YAP is highly active in hu-
man liver cancers (Marti et al., 2015; Rhee et al., 2018; Rizvi 
et al., 2018). Since both Nf2;Wwc1 DKO and BEC-specific 
Lats1/2 DKO mice developed iCCAs through activation of 
YAP/TAZ, we next sought to assess the expression of NF2, 
WWC1, LATS1/2 and YAP in human iCCA specimens. We 
found that NF2 was expressed in both hepatocytes and 
cholangiocytes, whereas YAP was predominantly detect-
ed in cholangiocytes in the human liver, as was the case in 
mouse liver (Fig. 5A) (Lee et al., 2016). Next, we examined 
the correlation between NF2 and YAP expression in immu-
nostained human iCCA specimens and found that 67% of 
iCCA samples (10 of 15) that were negative for NF2 showed 
high levels of nuclear YAP staining. However, among the 26 
samples positive for NF2 immunostaining, 13 were negative 
for nuclear YAP (Figs. 5B and 5C). Unfortunately, antibodies 
against LATS1/2 and WWC1 appropriate for IHC staining in 
normal human liver tissues were not commercially available; 
thus, expression of these components could not be tested in 
human specimens. Taken together, these results indicate that 
the expression of NF2 and YAP show an inverse correlation in 
human iCCA specimen.
DISCUSSION
HCC development has been relatively well studied, with ge-
netic mouse models of HCC outnumbering those for iCCA. 
Fig. 3. Biliary cell-specific depletion of LATS1/2 leads to iCCA development. (A) Representative images of H&E staining and IHC staining 
with antibodies against YAP, TAZ, and Ki67 in the liver of BEC-specific Lats1/2 DKO mice (black arrowheads indicate cholangiocytes; scale 
bars = 50 μm). (B) Images of co-IF staining with antibodies against CK19 and HNF4a (yellow arrowhead indicates CK19+/tdTomato+ cells 
and white arrowhead indicates CK19+/HNF4- cells; scale bars = 50 μm). (C) Images of Sirius red/Fast green staining in livers of BEC-specific 
Lats1/2 DKO mice (scale bars = 50 μm). (D) mRNA expression levels of the YAP target genes (Ankrd1, Ctgf and Cyr61) in livers of BEC-
specific Lats1/2 DKO mice.
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Fig. 4. iCCAs that develop in 
Nf2;Wwc1 DKO and BEC-specific 
Lats1/2 DKO livers resemble type 
2 iCCA in human patients. (A-C) 
Representative images of Alcian-
blue staining (A), IHC staining for 
S100P (B), and N-cadherin (C) in 
livers of 2- to 3-week-old mice 
of each genotype. Black circles 
indicate the ductular area in 
cancer (scale bars = 100 μm).
Fig. 5. IHC staining for NF2 and 
YAP in human iCCA. (A and B) 
Representative images of IHC 
staining with antibodies against 
NF2 and YAP in normal (A) and 
iCCA (B) tissues (black arrowheads 
indicate cholangiocytes; scale bars 
= 25 μm). (C) Table of NF2 and 
YAP staining scores (one-tailed P 
= 0.2401, Fisher’s exact test).
498  Mol. Cells 2020; 43(5): 491-499 
WWC1 and NF2 Prevent iCCA Development by Regulating YAP/TAZ
Jaeoh Park et al.
These studies, which highlighted the development of HCCs 
or mixed HCC/iCCA following albumin-Cre mediated pertur-
bation of the Hippo pathway, led to the discovery of Hippo 
signaling as a tumor-suppressor pathway for liver cancers 
in mice. Although hyperactivation of YAP/TAZ in mice leads 
to the conversion of hepatocytes into BEC-like cells upon 
albumin-Cre or adeno-Cre-mediated loss of Lats1 and Lats2 
in livers, iCCAs do not develop in these mouse models (Lee 
et al., 2016). Here, for the first time, we demonstrated iCCA 
development through activation of YAP/TAZ in both Nf2;W-
wc1 DKO and BEC-specific Lats1/2 DKO mice, establishing 
that YAP activation specifically in intrahepatic cholangiocytes 
drives early onset of iCCA in mice.
 The NF2/WWC1/FRMD6 complex is the most upstream 
element in the Hippo signaling pathway. Here, we found 
a drastic decrease in LATS activity in Nf2;Wwc1 DKO mice 
compared with mice with liver deletion of either Wwc1 or 
Nf2 alone. These results reflect the cooperative regulation of 
LATS activity in vivo by the two mammalian upstream Hippo 
pathway components, NF2 and WWC1. Nf2;Wwc1 DKO 
mice also showed marked acceleration of iCCA development 
compared with Nf2 KO mice. As was previously reported, 
deletion of Wwc1 alone did not induce the development 
of liver cancer. Therefore, we suggest that WWC1 acts as a 
limiting factor rather than a necessary factor in regulating the 
activity of LATS. Additionally, given that WWC1, which serves 
as part of a negative feedback loop in the Hippo pathway, is 
a prime target of YAP activation, YAP activation may further 
potentiate the role of WWC1 as a ‘brake’—a key factor in de-
termining sustained activity of the Hippo pathway (Park et al., 
2016). The cooperative actions of NF2 and WWC1, revealed 
by their loss in Nf2;Wwc1 DKO mice, is also supported by a 
recent report that MORC2, a DNA methyltransferase, medi-
ates silencing of NF2 and WWC1 in human HCCs (Wang et 
al., 2018). Collectively, these findings provide direct evidence 
that NF2 and WWC1 synergize to prevent the development 
of YAP/TAZ-driven iCCA by regulating the activation of 
LATS1/2.
 In human liver cancer patients, both HCC and iCCA tumors 
highly express YAP and TAZ (Van Haele et al., 2019), and YAP 
activity correlates with poor prognosis of patients, metastatic 
potential, and chromosomal instabilities of iCCAs (Marti et 
al., 2015; Pei et al., 2015; Rizvi et al., 2018). Thus, we sought 
to establish a correlation between YAP and NF2 expression in 
human iCCA samples. Although the majority of NF2-negative 
patients were positive for nuclear YAP, significant p-values 
were not obtained because the number of specimens was 
too small. There might be additional explanations for these 
limitations. First, unlike the case in HCCs, NF2 expression is 
not fully repressed in iCCAs (Wang et al., 2018) and is up-
regulated by YAP/TAZ activation owing to negative feedback 
(Park et al., 2016). Second, we could not estimate NF2 activ-
ity by IHC. Finally, no WWC1 antibody suitable for IHC stain-
ing is commercially available; thus, we could not determine 
whether expression levels of NF2 and WWC1 are correlated 
with nuclear YAP in human iCCA tissue microarrays.
 In summary, we provide direct evidence that YAP/TAZ acti-
vation by deletion of Nf2 and Wwc1 or BEC-specific deletion 
of Lats1 and 2 induces iCCA development in mice. Therefore, 
NF2, WWC1, and LATS1 and -2 act synergistically to prevent 
iCCA development by repressing YAP/TAZ activities in the bile 
duct compartment.
Note: Supplementary information is available on the Mole-
cules and Cells website (www.molcells.org).
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